Q-omics provides the consensus-scored SHROOM2 profile across patient tissues and cancer cell-line models. SHROOM2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SHROOM2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SHROOM2 RNA expression shows 17,840 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where SHROOM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHROOM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHROOM2 survival associations across molecular data types. SHROOM2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHROOM2 RNA expression–survival associations across cancer types. High SHROOM2 expression shows unfavorable associations in SARC and STAD, but favorable associations in KIRC, READ, ACC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SHROOM2 RNA expression.
This table summarizes SHROOM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SHROOM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHROOM2 shows lower tumor expression in KIRC and higher tumor expression in HNSC, BRCA, BLCA, LUSC and LIHC. The HNSC box plot shows higher SHROOM2 RNA expression in tumor versus normal tissue (log2 FC = +0.673, t-test p < 0.001).
This table shows molecular features associated with SHROOM2 in patient tissues and cancer cell lines. In patient samples, SHROOM2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SHROOM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
